Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Recent News
Dr. Romee received his MD from Govt. Medical College Srinagar, India. He completed his postgraduate training and hematology and oncology fellowship at University of Minnesota where he also did his post-doctoral training in Dr. Jeffrey S. Miller’s laboratory. Afterward, he did an advanced bone marrow transplant fellowship at Washington University in Saint Louis where he stayed on as faculty before moving to Dana-Farber Cancer Institute.
VIDEO:
Rizwan Romee, MD, director of Dana-Farber’s Haploidentical Donor Transplant Program, discusses immunotherapy treatment options for advanced hematologic malignancies. Dr. Romee’s clinical focus includes advanced myeloid malignancies and NK cell based cellular therapy. Learn more about the Hematologic Oncology at Dana-Farber: http://www.dana-farber.org/hematologic-oncology-treatment-center/
As a translational physician-scientist, my long-term goals are to translate novel aspects of immunology to improve treatments for patients with advanced malignancies. We described human memory-like NK cells with enhanced anti-tumor activity and in a first in human clinical trial demonstrated safety and promising activity of these cells in advanced AML patients. In clinic we are currently testing these memory-like NK cells in combination with novel immune-modulatory agents in patients with advanced malignancies.
The primary focus of my lab-based research efforts is gene manipulation of the key immune cells including Natural Killer (NK) cells to enhance their anti-tumor function and modulate the tumor microenvironment (TME). We are also developing a novel class of immuno-cytokines aimed at selectively targeting the immuno-suppresive cells like MDSCs and Tregs.
I also lead our haploidentical transplant program and we are developing protocols using haploidentical donor transplantation as a platform to incorporate NK cell-based immunotherapy approaches.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions